Hua Zhao-Quan, Chang Yi-Jie
The First Hospital of Manchuria, Manchuria 021400, China.
Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(4):622-4.
To investigate the effects of Wuhuang Tangkangling on tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) in serum of patients with type 2 diabetes mellitus (T2DM).
One hundred cases of type 2 diabetes mellitus patients were randomly divided into two groups. The control group was treated with pioglitazone (15 mg x d(-1)) orally once a day in the morning, combined with insulin subcutaneous injection based on blood glucose level. The treatment group was treated with decoction of Wuhuang Tangkang Ling daily, 8 weeks as a course. TNF-alpha, IL-6, hs-CRP, fasting blood glucose (FBG) and postprandial blood glucose (PBG) were tested for two groups of patients before and after the treatment And other 50 healthy cases were tested for comparison.
Before treatment, the level of cytokine, FBG and PBG in the serum of patients with T2DM were significantly higher than healthy cases (P < 0.01). In treatment group, difference between before and after the treatment had statistical significance (P < 0.01); after treatment, difference between treatment group and control group had statistical significance (P < 0.01).
Wuhuang Tangkangling could significantly decrease the level of TNF-alpha, IL-6, hs-CRP, FBG and PBG in patients with T2DM, and could decrease blood glucose, anti inflammatory, and improve insulin resistance. According to testing these cytokines, a new criteria for evaluating the progress of T2DM and the treatment may be approached.
探讨五黄糖康灵对2型糖尿病(T2DM)患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和高敏C反应蛋白(hs-CRP)的影响。
将100例2型糖尿病患者随机分为两组。对照组于清晨口服吡格列酮(15mg·d⁻¹),每日1次,并根据血糖水平皮下注射胰岛素。治疗组每日服用五黄糖康灵汤剂,8周为1个疗程。分别检测两组患者治疗前后的TNF-α、IL-6、hs-CRP、空腹血糖(FBG)和餐后血糖(PBG),并与50例健康对照者进行比较。
治疗前,T2DM患者血清细胞因子、FBG和PBG水平显著高于健康对照者(P<0.01)。治疗组治疗前后差异有统计学意义(P<0.01);治疗后,治疗组与对照组差异有统计学意义(P<0.01)。
五黄糖康灵可显著降低T2DM患者的TNF-α、IL-6、hs-CRP、FBG和PBG水平,具有降糖、抗炎及改善胰岛素抵抗的作用。通过检测这些细胞因子,可能为评估T2DM病情进展及治疗提供新的标准。